http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Ionis reports first quarter 2021 financial results and recent business achievements
-
Ionis to hold first quarter 2021 financial results webcast
-
Ionis Pharmaceuticals (IONS) Begins Pivotal Clinical Study of Novel Antisense Medicine to Treat Patients with Alexander Disease
-
Ionis initiates pivotal clinical study of novel antisense medicine to treat patients with Alexander disease
-
Biogen (BIIB) Advances Leading Research in Spinal Muscular Atrophy with New Data at AAN
-
Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients
-
Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients
-
Ionis Pharmaceuticals (IONS) initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
-
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
-
Ionis Pharmaceuticals (IONS) Reports Data from Phase 2 Clinical Study of IONIS-PKK-LRx Met Primary and Secondary Endpoints
-
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
-
Ionis to present at upcoming investor conferences
-
Ionis Pharmaceuticals (IONS) announces Roche has decided to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease
-
Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx)
-
Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
-
Ionis reports fourth quarter and full year 2020 financial results and recent business achievements
-
Ionis to present at upcoming investor conferences
-
Ionis to hold 2020 financial results webcast
-
Biogen (BIIB) Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA in Patients Treated With Zolgensma
-
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
-
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
-
Ionis appoints Eugene Schneider, M.D., as executive vice president and chief clinical development officer
-
Ionis to present at 39th Annual J.P. Morgan Healthcare Conference
-
Stanley T. Crooke, Ph.D., M.D, to retire from Ionis to focus on his scientific interests and n-Lorem Foundation
-
Ionis highlights achievements, commercial strategy and technology advancements at Investor Day
-
Ionis to participate in virtual fireside chat at BMO 2020 Growth and ESG conference
-
Ionis announces initiation of the global Phase 3 BALANCE study for AKCEA-APOCIII-LRX in patients with familial chylomicronemia syndrome
-
Ionis to hold virtual investor day event
-
Ionis announces AstraZeneca's initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol
-
Ionis (IONS) announces AstraZeneca (AZN) has licensed ION455, an investigational antisense medicine being developed as potential treatment for NASH
-
Ionis announces third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH) enters development
-
Promising new data for Ionis' antisense medicine targeting PCSK9 presented at American Heart Association (AHA) Scientific Sessions 2020
-
Ionis' pioneering antisense technology to be featured in multiple presentations at American Heart Association (AHA) Scientific Sessions 2020
-
Ionis' antisense technology to be featured during virtual RNA at the Bench and Bedside II Conference
-
Ionis to present at upcoming virtual investor conferences
-
Ionis and Akcea Recognize FCS Awareness Day With Global Community Efforts to Celebrate Unsung Heroes
-
Ionis reports third quarter 2020 financial results and recent business achievements
-
Ionis Pharmaceuticals (IONS) Reports Pfizer (PFE) to Begin Phase 2b Clinical Study of Vupanorsen (AKCEA-ANGPTL3-LRx)
-
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen (AKCEA-ANGPTL3-LRx)
-
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product
-
Ionis' third novel antisense medicine for ALS, its first designed to treat a broad ALS population, begins clinical trial
-
Ionis to hold third quarter 2020 financial results webcast
-
Ionis Pharmaceuticals (IONS) antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
-
Ionis antisense medicine being evaluated in an investigator-initiated clinical study of COVID-19 patients in Brazil
-
Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
-
/C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./
-
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
-
Ionis Chief Scientific Officer Frank Bennett receives Lifetime Achievement Award from Oligonucleotide Therapeutics Society
-
Ionis Pharmaceuticals (IONS), Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics
-
Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics
